We’re experiencing issues with our datasets and search. We apologise for any inconvenience while we work to fix this.
TEVIMBRA BeOne Medicines AUS Pty Ltd
Product name
TEVIMBRA
Sponsor
Accepted date
Jul-2025
Active ingredients
tislelizumab
Summary of proposed indication
Tevimbra (tislelizumab) is used together with other chemotherapy medicines to treat people with extensive-stage small cell lung cancer (SCLC). It is proposed to be given as the first treatment after diagnosis.
Application type
C (new indication)
Publication date
Jul-2025